Volume 130, Issue 7, Pages 2189-2197 (June 2006) Serum Proteome to Predict Virologic Response in Patients With Hepatitis C Treated by Pegylated Interferon Plus Ribavirin  Valérie Paradis, Tarik Asselah, Delphine Dargere, Marie–Pierre Ripault, Michèle Martinot, Nathalie Boyer, Dominique Valla, Patrick Marcellin, Pierre Bedossa  Gastroenterology  Volume 130, Issue 7, Pages 2189-2197 (June 2006) DOI: 10.1053/j.gastro.2006.02.059 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Number of peaks that significantly changed in intensity between the beginning and the end of treatment according to genotype, stage of fibrosis, and grade of activity in the training group. Gastroenterology 2006 130, 2189-2197DOI: (10.1053/j.gastro.2006.02.059) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Variation in intensity of the cM32835 peak before beginning of treatment, at the end of treatment, and in the follow-up serum sample in the group of (A) sustained responders and (B) nonresponders in the training group. Gastroenterology 2006 130, 2189-2197DOI: (10.1053/j.gastro.2006.02.059) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 3 Number of peaks that significantly changed in intensity between the beginning (SO) and end of treatment (SEOT) and between the end of treatment (SEOT) and follow-up (SEFU) in all patients, the group of sustained responders, and the group of nonresponders in the training group. Gastroenterology 2006 130, 2189-2197DOI: (10.1053/j.gastro.2006.02.059) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 4 Box plot of peaks that distinguish the group of nonresponders from the group of sustained responders in the initial serum sample in the training cohort. Gastroenterology 2006 130, 2189-2197DOI: (10.1053/j.gastro.2006.02.059) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions